Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01161420 · ClinicalTrials.gov registry record · Phase 3

Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)

A Phase 3 study, sponsored by Inspire Medical Systems.

Completed
Registry status
Phase 3
Development phase
929
Enrollment target

NCT01161420 is a Phase 3 study that has completed, run by Inspire Medical Systems. The registered enrollment target is 929 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01161420, a Phase 3 study, has completed, sponsored by Inspire Medical Systems.

COMPLETED
Registry status
Phase 3
Development phase
929 participants
Enrollment target

Study Summary

The purpose of this clinical trial is to demonstrate long-term safety and efficacy of the Inspire system. The Inspire Upper Airway Stimulation (UAS) therapy is intended to treat moderate-to-severe obstructive sleep apnea by improving airway patency through stimulation of the hypoglossal nerve. Study objectives include demonstrating that the Inspire system improves key indices of sleep apnea in a pre-specified percentage of patients.

Interventions

  • DEVICE Inspire Upper Airway Stimulation System

Trial Details

FieldValue
Enrollment Target 929 participants
Start Date 2010-07
Est. Completion 2017-04
Phase Phase 3

Sponsor

Inspire Medical Systems

8 total trials

What the Registry Record Tells You About NCT01161420

The ClinicalTrials.gov registry entry for NCT01161420 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 929 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inspire Medical Systems, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Inspire Upper Airway Stimulation System is the first listed.

NCT01161420 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01161420 about?

NCT01161420 is a clinical study titled "Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)". The purpose of this clinical trial is to demonstrate long-term safety and efficacy of the Inspire system. The Inspire Upper Airway Stimulation (UAS) therapy is intended to treat moderate-to-severe obstructive sleep apnea by improving airway patency through stimulation of the hypoglossal nerve. Study...

What is the current status of trial NCT01161420?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 929 participants. The study started on 2010-07. Estimated completion is 2017-04.

What interventions are being tested in trial NCT01161420?

The interventions under investigation include: Inspire Upper Airway Stimulation System (DEVICE).

Who is sponsoring clinical trial NCT01161420?

This trial is sponsored by Inspire Medical Systems, which has 8 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.